Navigation Links
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Date:11/10/2008

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at

the ASH Meeting December 6-9, 2008

COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.

In addition, two abstracts on pre-clinical ofatumumab data have been accepted for presentation at poster sessions. All three ofatumumab abstracts are available on the ASH website at http://www.hematology.org.

ASH Sessions

Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial.

Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers.

Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on t
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces Results for the First Nine Months of 2008
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
4. Genmab A/S - Changes Board/Management/Auditors
5. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
6. Genmab Announces 2008 First Quarter Results
7. Passing of Genmab A/S Annual General Meeting
8. Genmab A/S - Notice to Convene Annual General Meeting
9. Genmabs 2007 Annual Report
10. Genmab Announces Year End 2007 Financial Results
11. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... first time, chemists have succeeded in measuring vibrational motion ... The study reveals how vibration of a single molecule ... , The study was performed at the University of ... University of Jyvskyl works as a visiting fellow under ... study. The second team was lead by Professor Eric ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... N.Y., Sept. 12 Fougera, a division of ... its Clotrimazole Cream USP,1%. The generic formulation compares ... in three sizes: 15g tubes (NDC # 0168-0133-15), ... # 0168-0133-46)., "The approval of Clotrimazole Cream ...
... 12 Acologix, Inc., a privately,held biopharmaceutical company, ... that AC-100, its therapeutic product,candidate derived from an ... promotes cartilage regeneration in large animal models. The,data ... on September,13, 2008 at the 30th ASBMR (American ...
... Pharmaceutical,Group (NYSE: SCR ), a leading manufacturer ... the patented anti-cancer biotech,product Endu in China, today ... Xiaojin Yin to Executive Vice President and Senior ... Li to the newly created,position of Vice President ...
Cached Biology Technology:Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 2Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 3Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources 2
(Date:8/21/2014)... ubiquitous skin fungus linked to dandruff, eczema and other ... to even further global reachesincluding Hawaiian coral reefs and ... vents. , A review in the scientific journal ... of the fungi of the genus Malassezia ... sequencing datasets from around the world. , University of ...
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... BATON ROUGE In a finding that has implications ... and planets elsewhere in the solar system, LSU Associate ... funded by the National Science Foundation, or NSF, this ... sediments of a lake that lies 800 meters (2600 ... sheet support "viable microbial ecosystems.", Given that more than ...
Breaking Biology News(10 mins):From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... (formerly Automated Vending Technologies) (Ticker: AVTC.PK) ( www.autoretail.com ) ... of Secure Automated Retailing Systems that feature MedBox,s patented ... provides extra security for automated retailing applications where the ... AVT worked with MedBox to integrate its ...
... to characterize the genes involved in wood formation in poplar ... of wood as a feedstock for biofuels production. ... the work of other biofuels researchers who develop better and ... Eric Beers, professor of horticulture and the lead investigator on ...
... Health & Science University Doernbecher Children,s Hospital are the ... reveal tiny white matter injuries in the developing brain ... identification of these lesions in the preterm human infant ... inform families sooner of the potential for complications. The ...
Cached Biology News:AVT Partners with MedBox to Provide New Biometric Fingerprint Recognition for Secure Automated Retailing 2Genomics of wood for biofuels production investigated 2First use of high-field MRI in developing brain reveals previously undetectable injuries 2